Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study

BACKGROUND: Treatment options for patients with recurrent/metastatic nasopharyngeal carcinoma (RM-NPC) are not clear after progression on previous treatment with PD-(L)1 inhibitor; critical gaps in evidence remain for such cases. Immunotherapy combined with antiangiogenic therapy has been reported t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Xi, Hua, Yi-Jun, Zou, Xiong, Chen, Xiao-Zhong, Zhang, Xi-Mei, Xu, Bei, Ouyang, Yan-Feng, Tu, Zi-Wei, Li, Hui-Feng, Duan, Chong-Yang, Zhang, Wei-Jing, You, Rui, Liu, You-Ping, Liu, Yong-Long, Yang, Qi, Huang, Pei-Yu, Wang, Shu-Ni, Fan, Jia, Chen, Ming-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319986/
https://www.ncbi.nlm.nih.gov/pubmed/37415845
http://dx.doi.org/10.1016/j.eclinm.2023.102043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319986/
https://www.ncbi.nlm.nih.gov/pubmed/37415845
http://dx.doi.org/10.1016/j.eclinm.2023.102043

Ejemplares similares